Beta has announced the successful completion of its initial test flights as part of a U.S. government initiative aimed at advancing electric vertical takeoff and landing (eVTOL) technology. These flights, which transported manufactured organs for United Therapeutics between Maryland and Virginia, covered approximately 275 nautical miles.
Beta's CEO, Kyle Clark, emphasized that these missions pave the way for routine medical applications of electric flight at lower costs nationwide. The eVTOL industry has long been viewed as a solution to urban congestion, with potential uses in medical transport, cargo delivery, and defense.
Beta is actively pursuing Federal Aviation Administration (FAA) certification, with expectations to achieve this by 2028 for its eVTOL aircraft, while a conventional takeoff and landing model is projected for certification in 2027.
Despite these advancements, Beta's stock has seen a significant decline, losing about half its value since its IPO in November, reflecting a broader downturn in the eVTOL sector, where competitors like Joby and Archer Aviation have also faced substantial stock price drops. The U.K.'s Vertical Aerospace has experienced an even steeper decline of 68%.
The challenges in securing FAA certification have led to delays, but the pilot program initiated by President Trump aims to expedite the approval process across eight projects in 26 states, with Beta participating in seven of them